Zydus Lifesciences Ltd., a global healthcare company known for its innovation-led approach, has announced a major milestone in veterinary medicine through its U.S. subsidiary. ZyVet®, the dedicated animal health arm of Zydus Pharmaceuticals (USA) Inc., has launched the first veterinary-approved generic version of Furosemide Tablets for dogs and cats.
Furosemide is one of the most widely prescribed diuretics in veterinary practice. It plays a crucial role in treating congestive heart failure, chronic fluid retention, edema, and pulmonary congestion arising from cardiac, renal, or systemic diseases in pets. Until now, veterinarians and pet owners had limited access to affordable generic alternatives, making this launch an important development for the animal health market.
ZyVet’s Furosemide Tablets are manufactured under stringent quality standards and are offered in multiple strengths, ensuring veterinarians have the flexibility to provide precise, patient-specific dosing. The company highlights that the product combines cost-effectiveness, consistent quality, and reliable availability, making it a strong alternative to higher-priced pioneer drugs.
The introduction of this product also addresses a significant gap in the veterinary pharmaceutical sector. Currently, fewer than 20% of animal health products have generic equivalents, even though the demand for affordable, high-quality therapies is steadily growing. By bringing a trusted, first-to-market generic of Furosemide, ZyVet is furthering its commitment to support veterinarians and pet owners with innovative and accessible treatment solutions.
Backed by Zydus Lifesciences’ 70 years of expertise in pharmaceutical R&D, regulatory approvals, manufacturing, and quality assurance, ZyVet continues to strengthen its presence in the animal health space. The launch of Furosemide Tablets not only expands its product portfolio but also reinforces its position as a leader in providing essential, affordable veterinary medicines.
